Nathalie Adda - 08 Oct 2021 Form 4 Insider Report for ENANTA PHARMACEUTICALS INC (ENTA)

Role
Sr. VP & Chief Medical Officer
Signature
/s/ Nathaniel S. Gardiner as attorney-in-fact
Issuer symbol
ENTA
Transactions as of
08 Oct 2021
Transactions value $
-$467,070
Form type
4
Date filed
13 Oct 2021, 18:39
Next filing
02 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ENTA Common Stock Options Exercise $585K +13.5K +49.93% $43.46 40.4K 08 Oct 2021 Direct
transaction ENTA Common Stock Sale -$943K -13.5K -33.3% $70.09* 26.9K 08 Oct 2021 Direct F1, F2
transaction ENTA Common Stock Options Exercise $176K +4.05K +15.02% $43.46 31K 11 Oct 2021 Direct
transaction ENTA Common Stock Sale -$285K -4.05K -13.06% $70.34* 26.9K 11 Oct 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -13.5K -18.61% $0.00 58.8K 08 Oct 2021 Common Stock 13.5K $43.46 Direct F4
transaction ENTA Stock Option (Right to Buy) Options Exercise $0 -4.05K -6.88% $0.00 54.8K 11 Oct 2021 Common Stock 4.05K $43.46 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in May 2021.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.30, inclusive.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $70.05 to $70.85, inclusive.
F4 100% of the shares subject to the option are fully vested and exercisable.

Remarks:

The reporting person undertakes to provide to Enanta Pharmaceuticals, Inc., any security holder of Enanta Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3 above.